Market news
TypeAll
SortNewest
Assets
NUVL
GSK secures first lung cancer approval, validating $10.6bn Nuvalent bet
Jideytro will now enter a lung cancer niche dominated by Pfizer’s Lorbrena.
Jul 23Yahoo Finance
NUVL
GSK Lands FDA Approval for Nuvalent-Acquired Jideytro for NSCLC
GSK secures early FDA approval for Jideytro, its first lung cancer therapy, backed by strong ARROS-1 data, and strengthens its precision oncology portfolio.
Jul 15Investing.comNUVL
Jul 10Investing.comNUVL
This is the newest page. Registered accounts read further back.